AvantGen is a San Diego-based biotechnology company founded in 2006 with Therapeutic and Research & Diagnostic divisions. With its proprietary and robust yeast display system, large natural human antibody database, fully human antibody (Germliner™) libraries and screening technologies, AvantGen’s Therapeutic Division is dedicated to novel human antibody discovery, antibody humanization, antibody affinity maturation and optimization, for therapeutic development. AvantGen collaborates with pharmaceutical and biotechnology companies to facilitate and speed their path to antibody-based therapeutic development through services, partnerships, and licensing.
Additionally, by combining AvantGen’s yeast display system and the alternate diversity obtained from the immune responses in rabbits, AvantGen has developed a novel platform to generate rabbit monoclonal antibodies with very high affinity and specificity. With this platform, AvantGen’s Research & Diagnostic Division is developing high quality rabbit monoclonal antibodies for high value diagnostic targets, for NIH’s proteomic projects, and providing services to pharmaceutical, biotech companies, and academic researchers for their needs in obtaining superior rabbit monoclonal antibodies.
The power of AvantGen’s technology platform has been well recognized by the National Institutes of Health (NIH), the biotech and pharmaceutical industry. AvantGen has received 18 SBIR Phase I and Phase II grant and contract awards to date from the NIH to develop novel antibodies against multiple targets for therapeutic, diagnostic and research reagent development. AvantGen has also successfully completed de novo antibody discovery, antibody humanization and optimizations for pharmaceutical, biotech companies, and academic institutions.